Horizons in therapy for corneal angiogenesis

Ophthalmology

Volumn 118, Issue 3, 2011, Pages 591-599

  Maddula, Surekha ^a   Davis, Don K ^a   Maddula, Soumya ^a   Burrow, Michael K ^a   Ambati, Balamurali K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTIBIOTIC AGENT; BEVACIZUMAB; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DOXYCYCLINE; ENDOSTATIN; HYDROCORTISONE; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW MOLECULAR WEIGHT HEPARIN; MIDOSTAURIN; MYDRIATIC AGENT; PARVOVIRUS VECTOR; PHOTOFRIN II; PLACEBO; PREDNISOLONE ACETATE; PREDNISONE; PROPOLIS; RANIBIZUMAB; RESVERATROL; SMALL INTERFERING RNA; SOMATOMEDIN; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VERTEPORFIN; VITAMIN D;

AMNION; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CATARACT; CELL TRANSPLANTATION; COMBINATION CHEMOTHERAPY; CORNEA NEOVASCULARIZATION; CULTIVATED LIMBAL EPITHELIAL TRANSPLANTATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GLAUCOMA; HUMAN; IMMUNOMODULATION; INFECTION; INFLAMMATION; LIMBAL STEM CELL TRANSPLANTATION; LOW LEVEL LASER THERAPY; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; VIRAL GENE THERAPY;

EID: 79952264878     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.01.041     Document Type: Article

References (49)

1. Y. Qazi, S. Maddula, and B.K. Ambati Mediators of ocular angiogenesis J Genet 88 2009 495 515
2. B.K. Ambati, M. Nozaki, and N. Singh Corneal avascularity is due to soluble VEGF receptor-1 Nature 443 2006 993 997 (Pubitemid 44646176)
3. R.J. Albuquerque, T. Hayashi, and W.G. Cho Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth Nat Med 15 2009 1023 1030
4. C. Cursiefen, L. Chen, and M. Saint-Geniez Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision Proc Natl Acad Sci U S A 103 2006 11405 11410 (Pubitemid 44156530)
5. B.K. Ambati, A.M. Joussen, and W.A. Kuziel Inhibition of corneal neovascularization by genetic ablation of CCR2 Cornea 22 2003 465 467 (Pubitemid 36759041)
6. B.K. Ambati, A. Anand, and A.M. Joussen Sustained inhibition of corneal neovascularization by genetic ablation of CCR5 Invest Ophthalmol Vis Sci 44 2003 590 593 (Pubitemid 36159703)
7. B.J. Brooks, B.K. Ambati, D.M. Marcus, and A. Ratanasit Photodynamic therapy for corneal neovascularisation and lipid degeneration Br J Ophthalmol 88 2004 840 (Pubitemid 38725605)
8. J.D. Sheppard Jr, R.J. Epstein, and F.A. Lattanzio Jr.Argon laser photodynamic therapy of human corneal neovascularization after intravenous administration of dihematoporphyrin ether Am J Ophthalmol 141 2006 524 529
9. K.C. Yoon principal investigator Photodynamic Therapy with Verteporfin for Corneal Neovascularization ClinicalTrials.gov Identifier NCT00471406 http://clinicaltrials.gov/ct2/show/NCT00471406?term= corneal+neovascularization&rank=8 Accessed October 7, 2010
10. R. Dana Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis) Trans Am Ophthalmol Soc 105 2007 330 343
11. P. Lu, L. Li, and G. Liu Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist Invest Ophthalmol Vis Sci 50 2009 4761 4768
12. R. Dana principal investigator Topical Avastin for Treatment of Corneal Neovascularization ClinicalTrials.gov Identifier NCT00559936 http://clinicaltrials.gov/ct2/show/NCT00559936 Accessed September 30, 2010
13. J.L. Bourges, F. Lallemand, and E. Agla Evaluation of a topical cyclosporine A prodrug on corneal graft rejection in rats Mol Vis 12 2006 1461 1466 (Pubitemid 46117008)
14. Lux Biosciences, principal investigator Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty ClinicalTrials.gov Identifier NCT00447642 http://www.clinicaltrials.gov/ct2/ show/NCT00447642?term=corneal+neovascularization&rank=16 Accessed on October 6, 2010
15. K. Ono, S. Yokoo, and T. Mimura Autologous transplantation of conjunctival epithelial cells cultured on amniotic membrane in a rabbit model Mol Vis 13 2007 1138 1143 (Pubitemid 47082968)
16. M. Kawashima, T. Kawakita, and Y. Satake Phenotypic study after cultivated limbal epithelial transplantation for limbal stem cell deficiency Arch Ophthalmol 125 2007 1337 1344 (Pubitemid 47606597)
17. N. Zakaria principal investigator Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency (LECT) ClinicalTrials.gov Identifier NCT00845117 http://www.clinicaltrials.gov/ct2/show/NCT00845117?term= corneal+neovascularization&rank=20 Accessed October 6, 2010
18. N. Aghdami Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients ClinicalTrials.gov Identifier NCT00736307 http://www.nextbio.com/b/search/ individualtrial.nb?id=NCT00736307 Accessed October 7, 2010
19. A.B. Raffiee The Role of Amniotic Membrane Transplantation in Ocular Chemical Burns ClinicalTrials.gov Identifier NCT00370812 http://www. clinicaltrials.gov/ct2/show/NCT00370812?term=corneal+neovascularization& rank=18 Accessed September 7, 2010
20. N. Yamada, R. Matsuda, and N. Morishige Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy Br J Ophthalmol 92 2008 896 900 (Pubitemid 351969664)
21. W.L. Chen principal investigator Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries ClinicalTrials.gov Identifier NCT01031888 http://www.clinicaltrials.gov/ct2/ show/NCT01031888?term=corneal+neovascularization&rank=14 Accessed October 7, 2010
22. E. Aydin, M. Kivilcim, and G.A. Peyman Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline Cornea 27 2008 446 453 (Pubitemid 351591483)
23. T.I. Kim principal investigator Corneal Thinning During Topical Bevacizumab Therapy ClinicalTrials.gov identifier NCT00515684 http://www.clinicaltrials.gov/ct2/show/NCT00515684?term= corneal+neovascularization&rank=12 Accessed October 8, 2010
24. C.H. Hsiao principal investigator Bevacizumab for the treatment of corneal neovascularization ClinicalTrials.gov identifier NCT00992849 http://clinicaltrials.gov/ct2/show/NCT00992849 Accessed September 30, 2010
25. M. Murata, S. Shimizu, S. Horiuchi, and M. Taira Inhibitory effect of triamcinolone acetonide on corneal neovascularization Graefes Arch Clin Exp Ophthalmol 244 2006 205 209
26. R. Dana principal investigator Effectiveness and Safety of Subconjunctival and Topical Ranibizumab for Treatment of Corneal Neovascularization ClinicalTrials.gov Identifier NCT00681889 http://www.clinicaltrials.gov/ct2/show/NCT00681889?term= corneal+neovascularization&rank=7 Accessed September 8, 2010
27. G. Gerten Bevacizumab (Avastin) and argon laser to treat neovascularization in corneal transplant surgery Cornea 27 2008 1195 1199
28. L.J. Lai, X. Xiao, and J.H. Wu Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model J Biomed Sci 14 2007 313 322
29. Y. Jin, M. Arita, and Q. Zhang Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators Invest Ophthalmol Vis Sci 50 2009 4743 4752
30. M. Keshavarz, A. Mostafaie, and K. Mansouri Inhibition of corneal neovascularization with propolis extract Arch Med Res 40 2009 59 61
31. T. Sen, S. Moulik, and A. Dutta Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7 Life Sci 84 2009 194 204
32. N. Gagliano, C. Moscheni, and C. Torri Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and Secreted Protein Acidic and Rich in Cysteine (SPARC) on human cultured glioblastoma cells Biomed Pharmacother 59 2005 359 364 (Pubitemid 41219649)
33. R. Riachy, B. Vandewalle, and E. Moerman 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor Apoptosis 11 2006 151 159 (Pubitemid 43291016)
34. F.E. Wang, G. Shi, and M.R. Niesman Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye Exp Eye Res 84 2007 922 933 (Pubitemid 46590134)
35. Y. Saishin, R.L. Silva, and K. Callahan Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model Invest Ophthalmol Vis Sci 44 2003 4989 4993 (Pubitemid 37315317)
36. S. Nakamura, Y. Chikaraishi, and K. Tsuruma Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt Exp Eye Res 90 2009 137 145
37. M.S. Palanki, H. Akiyama, and P. Campochiaro Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-be nzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration J Med Chem 51 2008 1546 1559 (Pubitemid 351438839)
38. C.A. Jones, N.R. London, and H. Chen Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability Nat Med 14 2008 448 453 (Pubitemid 351499393)
39. A.C. Lockhart, M.L. Rothenberg, and J. Dupont Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2010 207 214
40. H.B. Oliveira, T. Sakimoto, and J.A. Javier VEGF Trap(R1R2) suppresses experimental corneal angiogenesis Eur J Ophthalmol 20 2010 48 54
41. J.W. Bainbridge, A. Mistry, and M. De Alwis Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1 Gene Ther 9 2002 320 326 (Pubitemid 34285145)
42. J. Ideno, H. Mizukami, and A. Kakehashi Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model Int J Mol Med 19 2007 75 79
43. C.M. Lai, W.Y. Shen, and M. Brankov Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys Mol Ther 12 2005 659 668 (Pubitemid 41350147)
44. T. Igarashi, K. Miyake, and I. Masuda Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model Hum Gene Ther 21 2010 631 637
45. F. Bock, J. Onderka, and T. Dietrich Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation Graefes Arch Clin Exp Ophthalmol 246 2008 115 119 (Pubitemid 350162691)
46. P.D. Jani, N. Singh, and C. Jenkins Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis Invest Ophthalmol Vis Sci 48 2007 2030 2036 (Pubitemid 351261271)
47. N. Singh, E. Higgins, and S. Amin Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization Cornea 26 2007 65 72 (Pubitemid 46041566)
48. M.E. Kleinman, K. Yamada, and A. Takeda Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452 2008 591 597 (Pubitemid 351483358)
49. W. Cho, R.J. Albuquerque, and M.E. Kleinman Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth Proc Natl Acad Sci U S A 106 2009 7137 7142